Driving R&D Efforts Necessary to Gain FDA Approval of Cancer Treatment Assays

FRANKLIN, Tenn., August, 22, 2017 — Pierian Biosciences, the premier developer of life science technologies providing treatment directing data to aid physicians in selecting the most appropriate therapy for their patients with cancer, has named Norman Purvis, PhD, to a new position, executive vice president of research and development for the company.

“Norman has significant knowledge in the development of immunotherapy assays, which has been instrumental in the speed and precision of the development of the ImmunoINTEL platform,” says Robert Henry, president and chief executive officer of Pierian. “In addition, he has advanced the development of our ChemoINTEL platform in record time.”

ImmunoINTEL is Pierian Biosciences’ defined platform to provide more precise quantification and characterization of all tumor and immune populations within a tumor sample.  This platform holds the promise to deliver a more comprehensive description of the tumor microenvironment and immune landscape allowing physicians to better stratify patients and guide the selection of immunotherapies.  ChemoINTEL is the company’s chemosensitivity assay designed to accurately predict a patient’s response to chemotherapy. Pierian Biosciences is also developing PathwayINTEL detailing the functional biomarkers that predict the outcome of a targeted biologic therapy.

Purvis will lead all platform operations of the company’s R&D teams to improve existing IVD product lines as well as initiate new product development. Working directly with Dr. Mark Gelder, chief medical officer, Purvis and the clinical team are working toward achievement of Food and Drug Administration Premarket Approval applications of In Vitro Diagnostic (IVD) products.

Prior to being named executive vice president of research and development, Purvis was responsible for two of the Pierian Bioscience platforms, ChemoINTEL and ImmunoINTEL. Before joining the company, he was the vice president of core technology for IncellDx in Menlo Park, California. He holds a PhD in chemical engineering from Vanderbilt University, and a master’s degree in biomedical engineering, also from Vanderbilt.

 About Pierian Biosciences

Based in Franklin, Tenn., Pierian Biosciences is a privately held life sciences company offering the development and delivery of innovative, treatment-directing information, allowing providers to design patient-specific strategies that improve outcomes, quality of life and lower the cost of cancer care. The company’s technology includes the ChemoINTEL, ImmunoINTEL and PathwayINTEL platforms. Pierian Biosciences has a laboratory in Franklin, Tenn. and business offices in Franklin, Tenn and the UK. For more information visit http://pierianbio.com/.

Sharing this article